Duke Warning: Zyprexa-Diabetes Link

[Guest guest]

Any adverse effects that show up in government statistics are usually regarded

as only a small part of actual adverse events that occur.

 

 

 

http://www.ahrp.org/infomail/0702/12b.html

 

July 12, 2002

 

Duke Warning: Zyprexa-Diabetes Link

 

FYI

 

Since they arrived on the market in the 1990s, the so-called 'atypicial'

antipsychotic drugs have been wrapped in controversy and promotional hype by

drug companies and their paid professional spin masters who made bald claims

about their " favorable side effect profile " referring to them as " breakthrough "

" miracle " drugs that " balance the chemistry " in the brain.

 

In his book, Mad in America, Robert Whitaker relied on data available to the FDA

but not made known to most doctors who prescribe these drugs or to patients and

families. In clinical trials prior to FDA approval: " One in every 145 patients

who entered the trials --for risperidone, olanzapine, quetiapine, and a fourth

atypical called sertindole--died, and yet those deaths were never mentioned in

the scientific literature. " (p. 269)

 

It can be said, therefore, that contrary to what psychiatrists have been telling

patients and their families, the drugs prescribed for schizophrenia have severe

undesirable side effects. For some individuals, the side effects are fatal.

 

On July 1, 2002, Duke University issued a Press Release about the most recent

finding that links the new anti-psychotics to early onset diabetes. The team of

researchers--Elizabeth A. Koller, M.D. from the FDA, and Murali Doraiswamy, M.D.

from Duke-- analyzed FDA's adverse drug report database, MedWatch (which

receives 10% of adverse drug reports). They identified 289 cases of diabetes in

patients who had been prescribed olanzapine (a.k.a. Zyprexa), Eli Lilly's most

profitable drug.

 

The researchers reported: " Of the 289 cases of diabetes linked to the use of

olanzapine, 225 were newly diagnosed cases. One hundred patients developed

ketosis (a serious complication of diabetes), and 22 people developed

pancreatitis, or inflammation of the pancreas, which is a life-threatening

condition. There were 23 deaths, including that of a 15-year-old adolescent who

died of necrotizing pancreatitis, a condition where the pancreas breaks down and

dies. Most cases (71 percent) occurred within six months of starting the drug

and many cases were associated with moderate weight gain. "

 

The evidence from pre-marketing trials was also alarming: Whitaker wrote: " Of

the 2,500 patients in the trials who received olanzapine, twenty died. Twelve

killed themselves...Twenty-two percent suffered a 'serious' adverse event,

compared to 18 percent of the haloperidol patients. Two-thirds of the olanzapine

patients didn't successfully complete the trials.... " (p. 281)

 

According to the Duke researchers, many cases of diabetes have also been

reported with other antipsychotic drugs. In 1994, a Duke team first reported a

Diabetes link to the first 'atypical' antipsychotic drug, clozapine: last year,

384 reports of diabetes last year were associated with clozapine.

 

Whereas the British Medical Control Agency and the Japanese Health & Welfare

Ministry have issued warnings about the risk of diabetes for patients prescribed

Zyprexa, FDA has remained silent.

 

It is astounding to AHRP that the FDA has approved a clinical trial that exposes

teenagers-- who are not even diagnosed with schizophrenia-- to a drug that puts

them at risk of diabetes. The trial is being conducted at Yale University. [see,

AHRP complaint filed with the federal Office of Human Research Protection at:

http://www.researchprotection.org/Initiatives/YaleComplaint.html]

 

~~~~~~~~~~~~~~~~~~~~~~~~~~~~

 

http://www.eurekalert.org/pub_releases/2002-07/dumc-rwa062802.php

 

Antipsychotic Drug Might Be Linked to Diabetes

 

HealthNewsDigest.com - July 01, 2002

 

RESEARCHERS WARN ANTIPSYCHOTIC DRUG MIGHT BE LINKED TO DIABETES

 

DURHAM, N.C. & shy; Research from Duke University Medical Center suggests there

might be a link between at least one drug used to treat schizophrenia and the

onset of diabetes, a disease widely recognized as one of the leading causes of

death and disability in the U.S.

 

The drug, olanzapine (trade name Zyprexa), belongs to a relatively new family of

medications called atypical antipsychotics, which are used to treat

schizophrenia, paranoia and manic-depressive disorders. Other drugs in this

class include clozapine, risperidone, quetiapine and ziprasidone.

 

The researchers found metabolic abnormalities ranging from mild blood sugar

problems to diabetic ketoacidosis and coma in patients who had been prescribed

olanzapine, most of whom were otherwise not known to be diabetic. Diabetic

ketoacidosis (DKA) is a serious condition in which a person experiences an

extreme rise in blood glucose level coupled with a severe lack of insulin, which

results in symptoms such as nausea, vomiting, stomach pain and rapid breathing.

Untreated, DKA can lead to coma and even death.

 

" While our report does not prove a causal relationship between the drug and

diabetes, doctors should be aware of such potentially adverse effects, " said P.

Murali Doraiswamy, M.D., a psychiatrist at Duke and co-author of the study.

" We've found cases where patients had some very serious problems associated with

olanzapine, and at least 23 of them died. "

 

The findings appear in the July 2, 2002 issue of Pharmacotherapy. The research

was self-supported by the authors.

 

Doraiswamy and Elizabeth A. Koller, M.D., lead author of the study and a medical

officer at the FDA, queried the FDA MedWatch Drug Surveillance System, MEDLINE

(a biomedical database) and selected abstracts from national psychiatry meetings

over a period of eight years and identified 289 cases of diabetes in patients

who had been given olanzapine. Of the 289 cases of diabetes linked to the use of

olanzapine, 225 were newly diagnosed cases. One hundred patients developed

ketosis (a serious complication of diabetes), and 22 people developed

pancreatitis, or inflammation of the pancreas, which is a life-threatening

condition. There were 23 deaths, including that of a 15-year-old adolescent who

died of necrotizing pancreatitis, a condition where the pancreas breaks down and

dies. Most cases (71 percent) occurred within six months of starting the drug

and many cases were associated with moderate weight gain.

 

" The average age of adults showing signs of diabetes after taking olanzapine was

about 10 years younger than what is generally seen in the community, " said

Doraiswamy. " The younger age at onset plus the number of serious complications

and the improvements reported when the drug was stopped all suggest a link to

the disease. However, until we know if there are risk differences among drugs in

this class, it is important for physicians to watch all patients receiving this

medication for signs of diabetes so that it can be detected quickly and

managed. "

 

The study merely suggests an association between the drug and diabetes, said

Doraiswamy. Further studies are needed to offer more conclusive evidence of a

direct causal relationship. If future studies confirm the findings, he said that

perhaps the FDA should consider including a stronger warning label for these

drugs.

 

" The numbers are still sketchy since many adverse reactions are not reported to

the FDA and we don't have a good handle on how many people have actually

received these drugs, " he cautioned. " Atypical antipsychotics can be life saving

medications, but we need to learn more about their long-term side-effects. I

think this should be a high priority for investigation. "

 

Doraiswamy was part of a team from Duke that first reported a link between the

antipsychotic drug clozapine and the development of diabetes in a 1994 issue of

the American Journal of Psychiatry. Last year, Koller reported in the American

Journal of Medicine that the FDA had received 384 reports of diabetes associated

with the drug clozapine. According to the researchers, many cases of diabetes

have also been reported with other antipsychotic drugs.

 

Doraiswamy has previously received funding and consulting fees from all

companies that currently manufacture antipsychotic medications, including Eli

Lilly and Company, the manufacturer of Zyprexa.

 

© Health News Digest.com 2002

 

 

Gettingwell- / Vitamins, Herbs, Aminos, etc.

 

To , e-mail to: Gettingwell-

Or, go to our group site: Gettingwell

 

 

 

 

Mail Plus - Powerful. Affordable. Sign up now